🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart failure hospitalization reduction on semaglutide — 6 month update Page 4

Heart failure hospitalization reduction on semaglutide — 6 month update

ricardo_MIA Thu, Feb 22, 2024 at 4:53 AM 17 replies 2,290 viewsPage 4 of 4
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Feb 27, 2024 at 7:41 AM#16

Clinical perspective, offered as context rather than as advice.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Feb 27, 2024 at 10:41 AM
50 23DoseLogDan, SleepFixSam, PurityPaulOR and 47 others
Reply Quote Save Share Report
jennifer_SEA
Member
234
890
Nov 2024
Seattle, WA
Feb 27, 2024 at 4:35 PM#17
Dr.SurgeonPGH said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 61 pg/mL (normal, cardiac function preserved)
  • Lp(a): 31 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 156 to 86 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

1 24Dr.ReproEndo
Reply Quote Save Share Report
NauseaFreeNow
Member
345
1,234
Aug 2024
Indiana
Feb 28, 2024 at 1:28 AM#18
Dr.SurgeonPGH said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
Last edited: Feb 28, 2024 at 5:28 AM
2 0Dr.PulmRoch, maya_sedona
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Feb 28, 2024 at 10:21 AM#19
Dr.SurgeonPGH said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Genuinely useful, thank you. I had the facts and not the framework.

3 1wanda_boise, NurseAsh_DET, BenResearch_OR
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 28, 2024 at 7:14 PM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.

25 23PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 22 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register